KRAS and neoplasm: We showed that most of the internalized anti-KRAS antibodies are localized in the cytoplasm and not endosomes, and that the antibody altered endogenous KRAS localization from the inner plasma membrane to the cytoplasm in tumor cells harboring KRAS p.Gly12Val mutation.